The oncology data business is moving fast — and the companies that control the electronic medical record are quickly becoming the ones that control the future of cancer care.
Flatiron Health’s OncoEMR platform has quietly become one of the most strategically contested pieces of real estate in health technology. Over the past several years, the company has struck a string of integrations with major diagnostics players — Guardant Health, Natera, and most recently Abbott — embedding genomic and molecular testing directly into the workflows used by thousands of community oncologists across the United States. The cumulative effect is something that looks less like a software platform and more like a nervous system for precision oncology.
A Platform Becoming an Ecosystem
Start with the numbers. Flatiron’s network now spans more than 1,600 community cancer care centers and roughly 4,700 providers across North America. That’s not academic medicine. That’s the front lines — the oncology offices where most Americans actually receive their cancer treatment, far from the major research hospitals that tend to dominate the headlines.
Into that network, Guardant Health moved first in a meaningful, public way. The company’s genomic profiling tests were integrated directly into OncoEMR, giving providers a streamlined path from ordering to results without leaving the platform they already use every day. Beta testing told a compelling story: over 75 percent utilization compared to traditional ordering workflows. “Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” Guardant’s chief commercial officer Chris Freeman said at the time, noting the platform’s reach to “almost 40 percent of U.S. community oncologists.”
James Hamrick, MD, MPH, Vice President of Clinical Oncology at Flatiron, put it plainly: the goal is expanding “possibilities at the point of care.” That phrase — point of care — keeps coming up. It’s not accidental.
Natera, Abbott, and the Race to Integrate
Natera followed with its own integration, bringing its oncology testing portfolio into OncoEMR for over 4,500 cancer care providers. Flatiron’s Quincy Weatherspoon, vice president and general manager of point of care solutions, framed the company’s philosophy succinctly: “We aim to equip providers with smart, connected tools that enhance care delivery without adding complexity,” he noted.
Then came Abbott. The medical device giant integrated its Precision Oncology portfolio into OncoEMR, extending its reach across Flatiron’s full North American network. Abbott has been vocal about its broader thesis — that diagnostics shouldn’t be treated as a supporting actor in cancer care. The company has argued that diagnostics are, in fact, the front door in oncology. Getting embedded inside OncoEMR is a direct expression of that belief.
That’s the catch, isn’t it? Each of these integrations makes clinical sense on its own terms. But together, they’re also a land grab — a competition to become the default test ordered when an oncologist opens a patient chart.
The Data Layer Underneath It All
Still, the integrations are only part of the story. What Flatiron is building in parallel — and what may ultimately prove more valuable — is a real-world data infrastructure of remarkable depth.
The company’s Panoramic Database now holds more than 420,000 longitudinal patient records specifically for prostate and bladder cancer. At the ASCO GU 2026 conference, Flatiron presented research drawing on that dataset to illuminate how genitourinary cancers are actually being treated in the wild — across disease states, biomarker profiles, and treatment types. “By capturing this real-world complexity at scale through our Panoramic Database, we’re generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape — enabling them to deliver personalized medicine to any patient that is in front of them,” the company stated.
Real-world evidence has become the coin of the realm in oncology drug development. Clinical trials, by design, enroll narrow populations. The messy, comorbid, undertreated patients who fill community oncology waiting rooms rarely make the cut. Flatiron’s dataset captures those patients — and that’s precisely what makes it valuable to regulators, pharmaceutical companies, and now diagnostics firms.
Partnering on What Comes Next
Perhaps the most forward-looking move in this space is Flatiron’s partnership with Exact Sciences to advance evidence generation for the Oncodetect molecular residual disease test. The collaboration enrolled its first patient in a study targeting 1,350 participants across multiple solid tumor types — a significant undertaking aimed at proving out MRD testing in real clinical settings.
“Our collaboration with Flatiron Health represents a significant step in advancing cancer diagnostics, with a particular focus on MRD,” said Brian Baranick, general manager of Precision Oncology at Exact Sciences, in a release announcing the deal. Molecular residual disease detection — the ability to find traces of cancer DNA in the blood after treatment — is one of the most hotly anticipated frontiers in oncology. If Oncodetect can generate the clinical evidence it needs through this study, the commercial implications are enormous. And Flatiron, with its data infrastructure and provider network, is positioned to benefit regardless of which tests ultimately win.
What It All Adds Up To
Zoom out, and a clear picture emerges. Flatiron isn’t just an electronic medical records company anymore — if it ever really was. It’s become the connective tissue between diagnostics manufacturers hungry for clinical adoption and the community oncologists who, collectively, treat the vast majority of cancer patients in this country. Every integration deepens that position. Every dataset makes the platform more defensible.
The question worth sitting with: as more of oncology’s critical decision-making infrastructure consolidates inside a single platform, who ultimately benefits most — the providers, the patients, or the companies whose tests are one click away from becoming the default?
That’s not a knock on what Flatiron is building. It’s a genuinely important question. And the answer, like most things in cancer care, is probably more complicated than any single press release will admit.
